CGEN stock up 135% faces $44M trim by Kynam Capital

What happened: In the fourth quarter of 2026, Kynam Capital sold 1,059,375 shares of CG Oncology (CGON), a biotech company, for an estimated $43.84 million. This sale, representing a 135% increase in CGON's stock price, reduced Kynam's position value by $41.50 million. Separately, DAFNA Capital Management sold 222,847 shares of SNDX, another biotech company, for roughly $4 million.

Market impact: The significant sell-off by Kynam Capital, a major investor in CGON, has led to a re-evaluation of the stock's valuation. This move may signal a shift in investor sentiment towards the biotech sector, potentially impacting other companies in the space. The decrease in DAFNA's SNDX position, while smaller in scale, also indicates some profit-taking in the sector.

What to watch next: Upcoming catalysts include CGON's earnings release on March 15, 2027, which will provide insights into the company's financial health and potential growth. Additionally, investors should monitor the FDA's decision on CGON's drug candidate, expected in Q2 2027, which could significantly impact the stock's performance. Lastly, the broader biotech sector's performance, as indicated by the iShares Nasdaq Biotechnology ETF (IBB), will provide a gauge of investor sentiment towards the sector as a whole.